The Director, Health Economics & Outcomes Research (HEOR) leads the strategic development & execution of high-quality evidence for an enterprise-critical gene therapy in retina diseases. He or she directly contributes to the launch evidence required for JCA and HTA, and serves as the brand/asset leader representing HEOR on cross functional asset/brand teams,   ensuring HTA/payer evidence requirements are reflected in the overall asset strategy. He or she may be accountable for  more than one asset and/or   indication, and oversees evidence alignment across key international markets.   

Responsibilities

Oversees the design and conduct, of projects and effectively communicates the findings and strategic impact of findings to internal and external audiences

• Provides product leadership to HEOR strategic direction for consistent with business goals established in conjunction with the appropriate cross functional partners. These activities include but are not limited to: multi-stakeholder unmet need evidence, cost effectiveness and economic modeling, comparative effectiveness analyses, real world evidence, patient reported outcomes, and working with external experts to substantiate the case for gene therapy policy change,
• Ensures project plan integrates and aligns with the product strategic plans from matrix teams as well as commercial interests. Provides updates on execution of plans to product as well as functional management, owns, then shares project execution decisions. In the development of product strategic plans he/she liaises with other members of the product team to generate innovative ideas and create buy-in to strategies
• Accountable for end-to-end delivery of HEOR book of work under their remit, from strategy development to content pull through
• Accountable to ensuring strong partnership with all relevant HEOR COE functions to ensure a comprehensive HEOR voice is represented in cross-functional meetings
• Executive presence and ability to engage with senior leaders in a cross functional setting.